Tirzepatide

Description

Product Specifications

Form: Lyophilized peptide powder

Strength: Add the product-specific strength

Peptide Length: 39 amino acid residues

Peptide Classification: Synthetic lipidated dual GIPR/GLP-1R research peptide

Peptide Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys*-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂

One-Letter Representation: Y-X-EGTFTSDYSI-X-LDKIAQK*-AFVQWLIAGGPSSGAPPPS-NH₂, where X represents Aib and Lys* represents the lipid-modified Lys20 residue

Non-Natural Residues: Aib at positions 2 and 13

Lipid Modification: Lys20 is attached to 1,20-eicosanedioic acid through a linker containing γ-glutamic acid and two 8-amino-3,6-dioxaoctanoic acid units

C-Terminal Modification: Amidated

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: Approximately 4813.5 g/mol

CAS Number: 2023788-19-2

Purity: ≥99%, where confirmed through batch-specific HPLC analysis

Appearance: White to off-white lyophilized peptide powder

Intended Use: Laboratory research and analytical applications only

Research Applications

Analytical characterization using HPLC, UPLC, and LC-MS workflows

In vitro investigation of GIP receptor-binding behavior

In vitro investigation of GLP-1 receptor-binding behavior

Evaluation of dual-receptor ligand interactions under controlled assay conditions

Investigation of receptor-associated intracellular signaling

Structure-activity analysis of modified GIP-derived peptide sequences

Characterization of Aib substitutions and lipid-linked peptide architecture

Comparative assessment of Tirzepatide and structurally related research peptides

Peptide identity, purity, molecular weight, and structural integrity analysis

Evaluation of Lys20 side-chain modification using suitable analytical techniques

Stability profiling under controlled temperature, pH, buffer, and storage conditions

Quality Documentation

A batch-specific Certificate of Analysis and applicable analytical documentation should be available for each lot. Verify peptide identity, exact sequence, Aib residues at positions 2 and 13, Lys20 lipid-linked modification, C-terminal amidation, purity, molecular weight, formulation details, and batch information against the records supplied with the individual product.

Tirzepatide is a structurally modified peptide whose defined molecular identity includes the 39-residue peptide backbone, two Aib residues, C20 fatty di-acid conjugate, linker system, and C-terminal amide. Therefore, assign molecular specifications to the complete modified structure rather than to the unmodified peptide backbone alone.

Counterion-containing, hydrated, or otherwise formulated preparations may produce different analytical characteristics. Batch-specific HPLC and mass-spectrometric documentation should be treated as the final reference for product identity and specifications.

For Laboratory Research Use Only

This product is intended exclusively for controlled laboratory and in vitro research. Not for human or veterinary use. Not for diagnostic, therapeutic, clinical, cosmetic, or household applications.